Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy

被引：53

作者：

Kecmanovic, DM ^{[1
]}

Pavlov, MJ ^{[1
]}

Ceranic, MS ^{[1
]}

Sepetkovski, AV ^{[1
]}

Kovacevic, PA ^{[1
]}

Stamenkovic, AB ^{[1
]}

机构：

[1] Univ Belgrade, Surg Hosp 1, Clin Ctr Serbia, Dept Colorectal Surg, YU-11000 Belgrade, Serbia and Mont, Serbia

来源：

EJSO | 2005年 / 31卷 / 02期

关键词：

colorectal cancer; intraperitoneal chemotherapy; intraoperative intraperitoneal chemohyperthermia; peritonectomy;

D O I：

10.1016/j.ejso.2004.09.021

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose. Peritoneal. carcinomatosis from colorectal cancer is resistant to standard treatments and median survival time for patients ranges between 6 and 8 months. Aggressive cytoreductive surgery with hyperthermic intraperitoneal perioperative chemotherapy may increase median survival. Method. Patients undergoing cytoreductive surgery and perioperative hyperthermic chemotherapy (mitomycin C, intraoperativety; 5-fluorouracil early postoperatively) for peritoneal. carcinomatosis from cotorectal cancer from 1996 to 2003 were evaluated retrospectively. Results. From 1996 to 2003, 18 cytoreductive procedures were performed. The post-operative morbidity rate was 44.4% with no treatment related mortality. The median total operation time was 5 h 28 min (range: 3 h 20 min to 7 h 10 min). The median follow-up was 21 months. The median survival was 15 months. Conclusion. Surgical debulking and perioperative intraperitoneal chemotherapy improved survival with acceptable morbidity and mortality. Completeness of the resection was the most important prognostic indicator. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：147 / 152

页数：6